Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
about
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infectionPre- and Post-Transplant Antiviral Therapy (HBV, HCV)Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyEfficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-AnalysisConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CHepatitis C virus infection.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Hepatitis C in a New Era: A Review of Current TherapiesViral hepatitis and hepatocellular carcinoma: etiology and managementDynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents.Hepatitis C Virus and Liver Transplantation.Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from BelgiumRetrospective analysis of hepatitis C infected patients treated through an integrated care model.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.National assessment of early hospitalization after liver transplantation: Risk factors and association with patient survival.Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Hepatitis C virus genotype 4: Genotype 1's little brother.NS5A inhibitors for the treatment of hepatitis C infection.Developing therapies to treat hepatitis C infection in post-liver transplant recipients.Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
P2860
Q26740216-8ACE3322-11AE-4C2D-953E-D89D26B19C67Q26740319-313240DF-6139-468D-839D-2D4AC8FEB444Q28073100-5072D569-55D6-4CBE-B678-009A029B66A1Q28074783-679F84D4-89A2-4564-B4D7-411FAEDBC868Q28075544-C18D865A-57A9-4D03-8AB6-693D625E8536Q28076883-3DA23779-53BF-4378-9D89-A164ED072588Q30235178-30851F91-2AA3-4FC1-B1A9-F65625083925Q30235491-B00A03B1-7084-432C-8FA9-555E4AF2C908Q30355190-8D3E2B56-4019-4E70-80F7-B49A03FB16B9Q30399476-88F0F1B4-0596-459F-9B22-5805786F6A97Q31160142-D370E0B0-6FC7-41E1-8B2E-F7718703CD82Q31170657-04E7FC12-08A1-44B8-9DC9-BF62EFF421BBQ33585021-B7D1CE62-2480-4E51-8D3D-5A36A383F554Q33593219-D4F868E7-E6B9-45EE-BAFC-657268099DACQ33711206-43D9AA39-A862-4FA2-853D-8C21709E19EAQ33717116-E1756EF6-1D4C-48A9-9B8F-6FDC113A2AFBQ36165389-D7BAA9F3-C05B-4342-98C9-3CDBC17EB9F7Q36261373-918D8879-231D-4C0E-B244-C2ED2E9F4B12Q37338952-BBD4B39C-C1B2-4C36-8633-4958ED595D21Q37398996-E8F496C6-DE2B-43E5-B77E-5EC4DD13B6E1Q38610789-240E1C27-FB2A-4049-8221-C2A81DD897E9Q38688657-36BE79B6-48CC-4E07-9797-4209413CE494Q38716554-D630E3A4-6706-46E4-A907-63A4AD058E66Q38757351-CB7124C7-A57D-4891-A6D8-F323CA9827C6Q38763705-66972397-ACAC-4383-96A8-1238A1A66391Q38763789-677BBDC1-09D9-4980-996D-4E8838FBFB07Q38786027-9DCF1A49-3880-433E-99C2-1D166C806520Q38837174-04616426-2B6F-4359-BE59-3CE0A28D1B6FQ38850965-381A3860-1633-4A06-BDE7-8D664301E012Q38856649-B8A8F6F0-20ED-456B-93BE-8B5752A51F4EQ38860565-2AD07A41-AEEA-41B8-AEC5-E1008FA7C544Q38874771-8E463BC1-3CCA-4241-9FA6-337034C2AD5CQ38893244-1A3AE36B-9339-45F6-B182-B3597D174295Q38900917-A42F67B4-B64B-4404-93E3-CD8F639CD879Q38954096-A534A7AB-A815-4B45-9A47-61BC3C03909CQ38995024-FDFB9870-9A3A-434D-8A2A-9F859415D936Q39025320-39703F9D-6F5E-4351-9B21-C6BFF5292068Q39031350-1FCECD5E-84F6-44F8-B6CE-4AF2DDD896B7Q39055696-90869B0C-8FE5-425E-B858-8E59F58AFE33Q39108672-2D3B5692-2A22-43C0-8465-E9386D0A17D0
P2860
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Ledipasvir and sofosbuvir plus ...... el, randomised, phase 2 trial.
@en
type
label
Ledipasvir and sofosbuvir plus ...... el, randomised, phase 2 trial.
@en
prefLabel
Ledipasvir and sofosbuvir plus ...... el, randomised, phase 2 trial.
@en
P2093
P921
P1476
Ledipasvir and sofosbuvir plus ...... el, randomised, phase 2 trial.
@en
P2093
Bart van Hoek
Beat Müllhaupt
David Mutimer
Diana Brainard
Didier Samuel
Edward J Gane
Eric M Yoshida
Geoff McCaughan
Hadas Dvory-Sobol
Hans Van Vlierberghe
P304
P356
10.1016/S1473-3099(16)00052-9
P577
2016-02-18T00:00:00Z